Indoco Aims For Growth Despite Inconsistent Indian Pharma Market
Company Counts On Its COVID-19 Related Products To Perform
Failing to see the predicted recovery in the Indian pharma market, Indoco has re-evaluated its expectations, acknowledging that it may have to wait longer to see a return to pre-COVID domestic sales figures. The Indian company’s managing director, Aditi Panandikar, talks to Generics Bulletin about Indoco’s plans amidst inconsistent market trends.
